ISPE Issues Guidance for Packaging, Labeling, and Warehousing Facilities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ISPE Issues Guidance for Packaging, Labeling, and Warehousing Facilities


ePT--the Electronic Newsletter of Pharmaceutical Technology

The International Society of Pharmaceutical Engineering (ISPE) released guidance for the design, construction, and commissioning and qualification of packaging, labeling, and warehousing (PACLAW) facilities.  The ISPE Good Practice Guide: Packaging, Labeling, and Warehousing Facilities helps companies meet cGMP requirements for PACLAW facilities and avoid problems such as product adulteration, product mix-up, label mix-up, and misbranding.

“PACLAW facilities are very different from other types of pharmaceutical facilities, and up until this point, there has been no consistent guidance available to help companies ensure compliance,” said guide author Nick Davies in a July 3, 2012 press release. “With this ISPE guide, the industry finally has tools to ensure their PACLAW processes are efficient, compare their processes to established best practices, and demonstrate compliance to regulatory agencies.”

The guide gives direction on designing or reconfiguring PACLAW facilities using quality-by-design principles. It also explains how PACLAW facilities can comply with FDA’s systems-based approach, which uses a risk-based inspection model.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here